AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Recordati Industria Chimica e Farmaceutica

Report Publication Announcement Aug 1, 2022

4056_10-q_2022-08-01_da1daa9e-568c-45a8-8641-2eae223c1495.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

RECORDATI: PUBLIC DISCLOSURE

Milan, 1 st August 2022 – Following the press release issued on date 28th July 2022, please be informed that the Interim financial statements at 30th June 2022, approved by the Board of Directors on 28th July 2022 and the Independent Auditors' Report on the interim condensed consolidated financial statements at 30th June 2022 are available to the public, as of today, at the Company's registered office, on the Company's website (www.recordati.com) and on the storage mechanism ().

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2021 was € 1,580.1 million, operating income was € 490.2 million and net income was € 386.0 million.

For further information:

Recordati website: www.recordati.it

Investor Relations Investor Relations Media Relations
Federica De Medici Lucia Abbatantuoni Brunswick: Barbara Scalchi / Andrea Mormandi
(39) 02 48787146 (39) 02 48787213 (39) 02 9288 6200
e-mail: [email protected] e-mail: [email protected] e-mail: [email protected]

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office Via Matteo Civitali, 1 20148 Milano, Italy Ph. (39) 02 487871 Fax (39) 02 40073747 www.recordati.com

Share Capital € 26.140.644,50 fully paid-up Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150 Tax Code/VAT No. 00748210150 Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.l

Talk to a Data Expert

Have a question? We'll get back to you promptly.